Pantocalcin, tablets 500 mg 50 pcs

Pharmacodynamics

The spectrum of action is associated with the presence of gamma-aminobutyric acid in the structure. The mechanism of action is due to the direct effect of pantocalcin on GABA-receptor-channel complex. It has neurometabolic, neuroprotective and neurotrophic properties. Increases resistance of the brain to hypoxia and toxic substances, stimulates anabolic processes in neurons. It has anticonvulsant effect, reduces motor excitability with simultaneous ordering of behavior. Increases mental and physical performance.

It promotes normalization of gamma-aminobutyric acid in chronic alcohol intoxication and subsequent withdrawal of ethanol. It shows analgesic effect. It is able to inhibit acetylation reactions participating in mechanisms of inactivation of novocaine and sulfonamides; due to this it is possible to achieve prolongation of the action of the latter. It causes inhibition of pathologically increased bladder reflex and detrusor tone.

Pharmacokinetics

It is rapidly absorbed in the gastrointestinal tract. Time of reaching maximum concentration in blood plasma is 1 h. The highest concentrations are formed in the liver, kidneys, gastric wall, skin. It penetrates through blood-brain barrier.

It is not metabolized. It is excreted unchanged during 48 hours (67.5% of dose – in the urine, 28.5% – in the faeces).

Indications

Cognitive impairment in organic brain lesions and neurotic disorders;
as part of complex therapy for cerebrovascular insufficiency caused by atherosclerotic changes in cerebral vessels; senile dementia (initial form), residual organic brain damage in mature and elderly people;
cerebral organic failure in patients with schizophrenia (in combination with antipsychotics, antidepressants);
extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system (including Huntington’s chorea, hepatocerebral dystrophy, Parkinson’s disease);
consequences of neuroinfections and traumatic brain injuries (as part of complex therapy);
correction and prevention (cover-up therapy with simultaneous prescription) of side effects of antipsychotics; extrapyramidal neuroleptic syndrome (hyperkinetic and akinetic);
epilepsy with slowing of mental processes (in combination with anticonvulsants);
psycho-emotional overload, decreased mental and physical performance; to improve concentration and memory;
urinary disorders: enuresis, daytime urinary incontinence, pollakiuria, urgency;

Children:

mental retardation (delayed mental, speech, motor development or a combination thereof);
cerebral palsy;
stuttering (mainly clonic form);
epilepsy (as part of combination therapy with anticonvulsants, especially for polymorphic seizures and petit mal seizures).

Pharmacological effect

Pharmacodynamics

The spectrum of action is associated with the presence of gamma-aminobutyric acid in the structure. The mechanism of action is due to the direct effect of pantocalcin on the GABAB receptor-channel complex. It has neurometabolic, neuroprotective and neurotrophic properties. Increases the brain’s resistance to hypoxia and the effects of toxic substances, stimulates anabolic processes in neurons. It has an anticonvulsant effect, reduces motor excitability while regulating behavior. Increases mental and physical performance.

Helps normalize the content of gamma-aminobutyric acid during chronic alcohol intoxication and subsequent withdrawal of ethanol. Shows analgesic effect. It is capable of inhibiting acetylation reactions involved in the mechanisms of inactivation of novocaine and sulfonamides, thereby prolonging the action of the latter. Causes inhibition of the pathologically increased bladder reflex and detrusor tone.

Pharmacokinetics

Rapidly absorbed from the gastrointestinal tract. The time to reach the maximum concentration in the blood plasma is 1 hour. The highest concentrations are created in the liver, kidneys, stomach wall, and skin. Penetrates the blood-brain barrier.

Not metabolized. It is excreted unchanged within 48 hours
(67.5% of the dose taken – in urine, 28.5% – in feces).

Active ingredient

Hopantenic acid

Composition

1 tablet contains:
active ingredient:
hopantenic acid – 250.00 mg or 500.00 mg;
excipients:
magnesium hydroxycarbonate, calcium stearate, talc, potato starch.

Pregnancy

Contraindicated in the first trimester of pregnancy.

Contraindications

Hypersensitivity;
acute renal failure;
pregnancy (1st trimester).

Side Effects

Allergic reactions are possible (rhinitis, conjunctivitis, skin rashes).

Interaction

The effect of hopantenic acid is enhanced in combination with glycine and xydiphone.

Prolongs the effect of barbiturates; enhances the effects of drugs that stimulate the central nervous system, anticonvulsants, and the effect of local anesthetics (procaine).

Prevents the side effects of the following drugs: phenobarbital, carbamazepine, antipsychotics (neuroleptics).

Overdose

Symptoms: characterized by increased severity of side effects.

Treatment: gastric lavage, administration of activated carbon, symptomatic therapy.

Storage conditions

In a place protected from light at a temperature not exceeding 25°C.
Keep out of the reach of children.

Shelf life

4 years. Do not use after expiration date.

Manufacturer

Valenta Pharm JSC, Russia